Coldstream Capital Management Inc. Boosts Stock Position in Stryker Co. (NYSE:SYK)

Coldstream Capital Management Inc. grew its holdings in Stryker Co. (NYSE:SYK) by 1.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,890 shares of the medical technology company’s stock after purchasing an additional 75 shares during the period. Coldstream Capital Management Inc.’s holdings in Stryker were worth $2,004,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Precision Wealth Strategies LLC lifted its holdings in Stryker by 2.1% during the 4th quarter. Precision Wealth Strategies LLC now owns 3,114 shares of the medical technology company’s stock valued at $933,000 after buying an additional 65 shares in the last quarter. Gryphon Financial Partners LLC bought a new stake in shares of Stryker during the fourth quarter valued at approximately $348,000. Dimensional Fund Advisors LP boosted its holdings in shares of Stryker by 3.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 681,784 shares of the medical technology company’s stock valued at $204,166,000 after purchasing an additional 19,996 shares during the period. Avantax Advisory Services Inc. grew its stake in Stryker by 9.3% in the fourth quarter. Avantax Advisory Services Inc. now owns 9,884 shares of the medical technology company’s stock worth $2,960,000 after purchasing an additional 844 shares in the last quarter. Finally, Quotient Wealth Partners LLC purchased a new position in Stryker during the 4th quarter worth $1,535,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 0.6 %

NYSE:SYK opened at $365.10 on Wednesday. The company’s 50 day moving average is $340.21 and its two-hundred day moving average is $342.04. The company has a market cap of $139.13 billion, a PE ratio of 41.68, a P/E/G ratio of 2.77 and a beta of 0.91. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $365.96. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The firm had revenue of $5.42 billion for the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the prior year, the firm earned $2.54 EPS. The firm’s revenue was up 8.5% on a year-over-year basis. Analysts anticipate that Stryker Co. will post 12 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a $0.80 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio is currently 36.53%.

Insider Buying and Selling

In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of Stryker stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the sale, the chief financial officer now directly owns 2,852 shares in the company, valued at approximately $949,716. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Ronda E. Stryker sold 190,000 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total value of $61,457,400.00. Following the completion of the transaction, the director now owns 3,316,608 shares of the company’s stock, valued at approximately $1,072,790,023.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the sale, the chief financial officer now owns 2,852 shares in the company, valued at approximately $949,716. The disclosure for this sale can be found here. In the last quarter, insiders have sold 210,600 shares of company stock worth $68,330,400. 5.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SYK shares. Needham & Company LLC increased their price target on Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. The Goldman Sachs Group assumed coverage on shares of Stryker in a research report on Thursday, May 30th. They set a “neutral” rating and a $372.00 target price on the stock. Barclays upped their price target on shares of Stryker from $374.00 to $402.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. UBS Group lifted their price objective on shares of Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Morgan Stanley upped their target price on Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $378.58.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.